Incretin mimetics vie for slice of type 2 diabetes market.
Shaffer
Catherine
C
D058892:Adenosine Deaminase Inhibitors; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D018819:Dipeptidyl Peptidase 4; D054873:Dipeptidyl-Peptidase IV Inhibitors; D015195:Drug Design; D004345:Drug Industry / Q000191:economics / Q000639:trends; D052216:Glucagon-Like Peptide 1 / Q000819:agonists*; D006023:Glycoproteins / Q000037:antagonists & inhibitors*; D006801:Humans
D058892:Adenosine Deaminase Inhibitors; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006023:Glycoproteins; D052216:Glucagon-Like Peptide 1; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4